JAGSNPHARM — Jagsonpal Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹9.87bn
- IN₹8.48bn
- IN₹2.09bn
- 83
- 17
- 53
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.29 | ||
| Price to Tang. Book | 5.29 | ||
| Price to Free Cashflow | 28.41 | ||
| Price to Sales | 4.72 | ||
| EV to EBITDA | 39.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.62% | ||
| Return on Equity | 11.73% | ||
| Operating Margin | 9.07% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 1,585.68 | 1,879.46 | 2,175.84 | 2,367.14 | 2,087.02 | n/a | n/a | 4.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +9.07 | +116.73 | +10.35 | +55.78 | -24.42 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.
Directors
- Rajpal Kochhar CHM (58)
- Jasbir Kochhar DRC
- Govind Deo NID (59)
- Ishpal Ghai NID (66)
- Ashok Pati NID
- Bharat Singh NID (58)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- August 17th, 1978
- Public Since
- September 13th, 1996
- No. of Employees
- 940
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 26,457,111
- Address
- T 210J, Shahpurjat, NEW DELHI, 110049
- Web
- https://www.jagsonpal.com/
- Phone
- +91 1126494519
- Auditors
- For Walker Chandiok & CoLLP
Upcoming Events for JAGSNPHARM
Dividend For JGSN.NS - 5.0000 INR
Jagsonpal Pharmaceuticals Ltd Annual Shareholders Meeting
Q2 2025 Jagsonpal Pharmaceuticals Ltd Earnings Release
Q3 2025 Jagsonpal Pharmaceuticals Ltd Earnings Release
Similar to JAGSNPHARM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Jagsonpal Pharmaceuticals share price?
As of Today at 01:22 UTC, shares in Jagsonpal Pharmaceuticals are trading at IN₹375.00. This share price information is delayed by 15 minutes.
How has the Jagsonpal Pharmaceuticals share price performed this year?
Shares in Jagsonpal Pharmaceuticals last closed at IN₹375.00 and the price had moved by -18.23% over the past 365 days. In terms of relative price strength the Jagsonpal Pharmaceuticals share price has underperformed the S&P BSE 100 Index by -37.79% over the past year.
What are the analyst and broker recommendations for Jagsonpal Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Jagsonpal Pharmaceuticals dividend yield?
The Jagsonpal Pharmaceuticals dividend yield is 1.33% based on the trailing twelve month period.
Does Jagsonpal Pharmaceuticals pay a dividend?
Last year, Jagsonpal Pharmaceuticals paid a total dividend of IN₹5.00, and it currently has a trailing dividend yield of 1.33%.Looking ahead, shares in Jagsonpal Pharmaceuticals are due to go ex-dividend on 2024-09-06 and the next dividend pay date is 2024-10-18.
When does Jagsonpal Pharmaceuticals next pay dividends?
Jagsonpal Pharmaceuticals are due to go ex-dividend on 2024-09-06 and the next dividend pay date is 2024-10-18. The historic dividend yield on Jagsonpal Pharmaceuticals shares is currently 1.33%.
How do I buy Jagsonpal Pharmaceuticals shares?
To buy shares in Jagsonpal Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jagsonpal Pharmaceuticals?
As of the previous close price of IN₹375.00, shares in Jagsonpal Pharmaceuticals had a market capitalisation of IN₹9.87bn.
Where are Jagsonpal Pharmaceuticals shares listed?
Here are the trading details for Jagsonpal Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: JAGSNPHARM
What kind of share is Jagsonpal Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Jagsonpal Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jagsonpal Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Jagsonpal Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jagsonpal Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +7.18%.
As of the last closing price of IN₹375.00, shares in Jagsonpal Pharmaceuticals were trading +6.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jagsonpal Pharmaceuticals PE Ratio?
The Jagsonpal Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹375.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals' management team is headed by:
- Rajpal Kochhar - CHM
- Jasbir Kochhar - DRC
- Govind Deo - NID
- Ishpal Ghai - NID
- Ashok Pati - NID
- Bharat Singh - NID